

# Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue

---

Krbot Skorić, Magdalena; Crnošija, Luka; Adamec, Ivan; Barun, Barbara; Gabelić, Tereza; Smoljo, Tomislav; Stanić, Ivan; Pavičić, Tin; Pavlović, Ivan; Drulović, Jelena; ...

Source / Izvornik: **Clinical Autonomic Research: official journal of the Clinical Autonomic Research Society, 2019, 29, 321 - 328**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1007/s10286-018-0563-6>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:794185>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-01-04**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)





## Središnja medicinska knjižnica

**Krbot Skorić M., Crnošija L., Adamec I., Barun B., Gabelić T., Smoljo T., Stanić I., Pavičić T., Pavlović I., Drulović J., Pekmezović T., Habek M. (2019) *Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue. Clinical Autonomic Research: official journal of the Clinical Autonomic Research Society, 29 (3). pp. 321-328. ISSN 0959-9851***

<https://link.springer.com/journal/10286>

<https://doi.org/10.1007/s10286-018-0563-6>

<https://medlib.mef.hr/3628>

University of Zagreb School of Medicine Repository

<http://medlib.mef.hr/>

## **Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue**

Magdalena Krbot Skorić<sup>1,2</sup>, Luka Crnošija<sup>1</sup>, Ivan Adamec<sup>1</sup>, Barbara Barun<sup>1,3</sup>, Tereza Gabelić<sup>1,3</sup>, Tomislav Smoljo<sup>3</sup>, Ivan Stanić<sup>3</sup>, Tin Pavičić<sup>3</sup>, Ivan Pavlović<sup>3</sup>, Jelena Drulović<sup>4</sup>, Tatjana Pekmezović<sup>5</sup>, Mario Habek<sup>1,3</sup>

<sup>1</sup>University Hospital Center Zagreb, Department of Neurology, Referral Center for Autonomic Nervous System Disorders, Zagreb, Croatia

<sup>2</sup> Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia

<sup>3</sup>School of Medicine, University of Zagreb, Zagreb, Croatia

<sup>4</sup>Clinic of Neurology, CCS, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

<sup>5</sup>Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Serbia

Corresponding author:

Mario Habek, MD, PhD

Department of Neurology, University Hospital Center Zagreb

Kišpatićeva 12

HR-10000 Zagreb

Croatia

Phone/Fax: +38512388033; e-mail: mhabek@mef.hr

Word count: 2415

Number of references: 38

Number of tables: 3

Number of figures: 2

Authors' contributions

Study concept and design: Habek. Acquisition of data: Krbot Skorić, Crnošija, Adamec, Barun, Gabelić, Smoljo, Stanić, Pavičić, Pavlović, Drulović, Pekmezović, Habek. Analysis and interpretation of data: Krbot Skorić, Crnošija, Adamec, Barun, Gabelić, Smoljo, Stanić, Pavičić, Pavlović, Drulović, Pekmezović, Habek. Drafting of the manuscript: Habek. Critical revision of the manuscript for important intellectual content: Krbot Skorić, Crnošija, Adamec, Barun, Gabelić, Smoljo, Stanić, Pavičić, Pavlović, Drulović, Pekmezović, Habek.

Administrative, technical, and material support: Krbot Skorić, Crnošija, Adamec, Barun, Gabelić, Smoljo, Stanić, Pavičić, Pavlović, Drulović, Pekmezović, Habek.

Financial & competing interest disclosure

None of the authors have relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Funding

This study was funded by the Installation Research project HRZZ UIP-11-2013-2622 of the Croatian Science Foundation and University of Zagreb research support for the academic years 2017/2018.

## Abstract

**Objectives:** To investigate a possible association between autonomic dysfunction and fatigue in people with multiple sclerosis.

**Methods:** In 70 people with multiple sclerosis early in the disease course (51 females, mean age  $33.8 \pm 9.1$ ) quantitative sudomotor axon reflex test, cardiovascular reflex tests (heart rate and blood pressure responses to Valsalva maneuver and heart rate response to deep breathing) and the tilt table test were performed. Participants completed the Composite Autonomic System Score-31, Modified Fatigue Impact, Beck Depression and Epworth Sleepiness scales. Cut-off scores of  $\geq 38$  or  $\geq 45$  on the Modified Fatigue Impact Scale were used to stratify patients into a fatigued subgroup (N=17 and N=9, respectively).

**Results:** We found clear association between fatigue and subjective tests of the autonomic nervous system: fatigued patients scored significantly worse on Composite Autonomic System Score-31 and there was strong correlation between Modified Fatigue Impact Scale and Composite Autonomic System Score-31 ( $r_s = 0.607$ ,  $p < 0.001$ ). On the other hand, we found only modest association between fatigue and objective tests of the autonomic nervous system: there was a clear trend of lower sweating outputs on all measure sites, reaching statistical significance for distal leg and foot. We found weak correlations between Modified Fatigue Impact Scale and Valsalva ratio ( $r_s = -0.306$ ,  $p = 0.011$ ), Modified Fatigue Impact Scale and quantitative sudomotor axon reflex test of the forearm, proximal and distal lower leg ( $r_s = -0.379$ ,  $p = 0.003$ ,  $r_s = -0.356$ ,  $p = 0.005$  and  $r_s = -0.345$ ,  $p = 0.006$ , respectively). A multiple regression model showed that Composite Autonomic System Score-31, Beck depression scale and Epworth Sleepiness Scale were independent predictors of fatigue ( $p = 0.005$ ,  $p = 0.019$  and  $p = 0.010$ , respectively).

**Conclusion:** These results suggest that people with multiple sclerosis, already early in their disease course, suffer from objective and subjective impairments of the autonomic nervous system and suggest an association between autonomic nervous system impairment and multiple sclerosis related fatigue.

**Key words:** Fatigue, depression, sleep, multiple sclerosis

## Introduction

Fatigue is one of the most common symptoms of many neurological conditions and it is defined as extreme and persistent mental and/or physical tiredness, weakness or exhaustion (1). It can be primary, when it is considered to be part of the underlying neurological condition, or secondary, when it results from the presence of other concomitant circumstances or diseases (2).

Fatigue is one of the most frequent and the most burdensome symptoms of multiple sclerosis (MS) (3). Multiple sclerosis related fatigue (MSRF) is reported in up to 80% of the people with MS (pwMS), and over 55% of patients report fatigue as the worst symptom experienced from MS (4). Several MS specific processes may be responsible for primary MSFR, like impaired interactions between functionally related cortical and subcortical areas, activation of proinflammatory cytokines and dysregulation of the neuroendocrine system (5, 6, 7). However, a substantial proportion of pwMS also have concomitant depression and sleep disorders, which are strongly related to secondary MSRF (8, 9).

It has recently been suggested that the dysregulation of the autonomic nervous system (ANS) can lead to many MS-related clinical symptoms/comorbidities, including fatigue, depression and sleep disorders (10). Also, it has been demonstrated that ANS dysfunction is frequent in MS and it is present even in the earliest stages of the disease, with parasympathetic dysfunction present in 5 %, sympathetic in 42.6 % and sudomotor in 32.7 % of patients (11).

With the hypothesis that ANS dysfunction is an important contributor to MSRF, we aimed to investigate the role of ANS dysfunction in MSRF, taking into consideration the presence of depression and sleep disorders.

## Methods

Patients who participated in the BACIS project (12), in which consecutive patients with CIS were recruited into a two-year prospective clinical and neurophysiological follow-up from October 2014 until April 2016, were asked to participate in an MS comorbidities substudy at month 24 visit. All patients signed informed consent and the study was approved by Ethical Committees of the University Hospital Center Zagreb and the University of Zagreb, School of Medicine.

During the month 24 visit, testing of the ANS was performed. It consisted of Quantitative Sudomotor Axon Reflex Test (QSART) performed with Q-Sweat (WR Medical Electronics Co Maplewood, MN, USA) (13), testing of cardiovascular reflexes (heart rate and blood pressure responses to Valsalva maneuver and heart rate response to deep breathing) and the tilt table test (Task Force Monitor (TFM), CNSystems Medizintechnik AG, Austria) (13,14). Composite Autonomic Scoring Scale (CASS) was utilized to quantify autonomic dysfunction (15).

Following ANS testing, 70 participants filled in validated Croatian versions of the Composite Autonomic System Score-31 (COMPASS-31) (16), the Modified Fatigue Impact Scale (MFIS), the Beck depression scale (BDI-2) and Epworth Sleepiness Scale (ESS) (17). Clinically relevant BDI-2 result was considered if the score was  $>18$  (18).

Previous studies have used cut-off scores of  $\geq 38$  or  $\geq 45$  on the MFIS to define fatigue, so in our analysis, we used both cut-off points in order to stratify patients into a fatigued

subgroup (N=17 and N=9, respectively) and a non-fatigued subgroup (N=53 and N=61, respectively) (19,20). For each participant, Expanded Disability Status Scale (EDSS) and current use of disease modifying therapy (DMT) was noted.

The primary objective was to evaluate differences in ANS tests and COMPASS-31, BDI-2 and ESS between fatigued and non-fatigued subgroups.

Secondary outcomes were to correlate MFIS with objective tests of ANS function and subjective measures of dysautonomia (COMPASS-31), depression (BDI-2) and daytime sleepiness (ESS).

Finally, in order to examine the influence of age, sex, depression, daytime sleepiness, autonomic symptom burden and current use of DMT on the fatigue measured with MFIS, a multiple linear regression model was used.

### Statistical analysis

Statistical analysis was performed using the IBM SPSS software, version 20. The Kolmogorov–Smirnov test was applied to test whether the data has a normal distribution. Differences in the distribution of qualitative variables were determined with the  $\chi^2$  test (sex), while the differences in quantitative variables were determined with the use of parametric t test (age, respiratory sinus arrhythmia (RSA), Valsalva ratio (VR), QSART results) or nonparametric Mann–Whitney (EDSS, CASS, ESS, BDI-2, COMPASS-31). To determine the correlation between the MFIS variable and other variables (age, RSA, VR, QSART, COMPASS-31, CASS, ESS, BDI-2, EDSS) the Spearman correlation method was used. Multiple linear regression model based on six predictors (age, sex, depression defined as BDI-2 score >18, ESS, total sum of COMPASS-31 and current use of DMT) was used in order to determine significant predictors for the presence of fatigue measured with MFIS and its subtypes (physical fatigue, cognitive fatigue and psychosocial fatigue). Also, additional regression analysis for every domain of COMPASS-31 was performed with previously mentioned predictors in the model. For the predictors in multiple regression models, p values less than 0.05 were considered as significant. For analysis that included more comparisons on the same set of data, p values corrected with Bonferroni correction were considered as significant.

## Results

Baseline patients' characteristics are presented in table 1. Thirty-five (50%) patients were on DMTs (7 on teriflunomide, 8 on dimethyl fumarate, 6 on interferon beta, 13 on glatiramer acetate and 1 on alemtuzumab).

### Descriptive measures for patients with and without fatigue

Differences in all studied parameters between fatigued and non-fatigued MS patients defined either as MFIS  $\geq 45$  or  $\geq 38$  are presented in table 2. Fatigued patients according to the both cut-off values were older and scored significantly worse on BDI-2 and COMPASS-31. There was a clear trend of lower sweating outputs at all measure sites, reaching statistical significance for distal leg (MFIS  $\geq 45$ ) and foot (MFIS  $\geq 38$ ).

### Correlations of subjective and objective ANS tests

Results of the correlation between parameters of objective autonomic nervous system testing and different domains of COMPASS-31 are presented in Supplementary table 1. There was statistically significant correlation between the RSA and bladder domain of the COMPASS-31 ( $r_s = -0.358$ ,  $p = 0.002$ ) and between QSART of the proximal leg and gastrointestinal domain ( $r_s = -0.383$ ,  $p = 0.002$ ), QSART of the distal leg and secretomotor domain ( $r_s = -0.394$ ,  $p = 0.002$ ) and QSART of the distal leg and the gastrointestinal domain ( $r_s = -0.381$ ,  $p = 0.002$ ).

Correlations of fatigue with objective and subjective ANS tests, depression and daytime sleepiness

We found significant correlations between MFIS and age ( $r_s = 0.329$ ,  $p = 0.005$ ), MFIS and VR ( $r_s = -0.306$ ,  $p = 0.011$ ), MFIS and QSART of the forearm, proximal and distal lower leg ( $r_s = -0.379$ ,  $p = 0.003$ ,  $r_s = -0.356$ ,  $p = 0.005$  and  $r_s = -0.345$ ,  $p = 0.006$ , respectively) (Figure 1), MFIS and BDI-2 ( $r_s = 0.756$ ,  $p < 0.001$ ), and MFIS and COMPASS-31 ( $r_s = 0.607$ ,  $p < 0.001$ ) (Figure 2). Also, there was statistically significant correlation between the MFIS and every domain of COMPASS-31 (orthostatic intolerance,  $r_s = 0.426$ ,  $p < 0.001$ ; vasomotor,  $r_s = 0.387$ ,  $p = 0.001$ ; secretomotor,  $r_s = 0.409$ ,  $p < 0.001$ ; gastrointestinal,  $r_s = 0.503$ ,  $p < 0.001$ ; bladder,  $r_s = 0.433$ ,  $p < 0.001$ ; pupilomotor,  $r_s = 0.720$ ,  $p < 0.001$ ).

Regression analysis

A multiple regression model was used to predict the presence of fatigue measured with the MFIS based on age, sex, depression defined as BDI-2 score  $>18$ , daytime sleepiness measured with ESS, autonomic dysfunction measured with COMPASS-31 and current use of DMT. Multiple regression model statistically significantly predicts the MFIS variable ( $F = 11.366$ ,  $p < 0.001$ ), with a  $R^2 = 0.536$ . Total sum of COMPASS-31, BDI-2 and ESS were independent predictors for the presence of fatigue measured with the MFIS ( $B = 0.464$ ,  $p = 0.005$ ,  $B = 17.344$ ,  $p = 0.019$  and  $B = 1.111$ ,  $p = 0.01$ , respectively). As MFIS can distinguish different types of fatigue (physical, cognitive and psychosocial) we further analysed influence of the studied parameters on these three types of MSRF. There was statistically significant correlation between the age and cognitive fatigue ( $r_s = 0.295$ ,  $p = 0.013$ ). Results of the regression analysis with different types of fatigue (physical, cognitive and psychosocial) as outcome variables are presented in Table 3. The only statistically significant predictor for cognitive fatigue was COMPASS-31, while statistically significant predictors for physical fatigue were ESS, BDI-2 and COMPASS-31.

Finally, in order to examine the possible influence of age, sex, depression defined as BDI-2 score  $>18$ , ESS, different domains of the COMPASS-31 and current use of DMT on the fatigue measured with MFIS the regression analysis was performed (Supplementary table 2). The regression analysis showed that that orthostatic intolerance and bladder domains of the COMPASS-31 were not statistically significant independent predictors of MFIS, while other domains (vasomotor, secretomotor, gastrointestinal and pupilomotor) were.

**Discussion**



We have found that pwMS who suffer from fatigue score significantly worse on COMPASS-31, a patient-related outcome evaluating autonomic symptoms. Furthermore, COMPASS-31 independently predicted fatigue, regardless of depression and/or daytime sleepiness. Several studies used different objective tests of ANS in order to investigate possible role of ANS dysfunction in development of MSRF. Initial studies focused on correlation of different tests of cardiovascular autonomic function (heart rate and blood pressure variability, responses to postural changes, pressure tests, the Valsalva maneuver, deep breathing, and hyperventilation), and were largely negative, or if positive, confounded by age effects on autonomic tests (21,22). In one study, the consistent decrease of blood pressure response to sustained grip in combination with increased fatigue was observed (23). Our study confirmed these observations, as we were unable to show differences in any of the studied cardiovascular reflexes between fatigued and non-fatigued patients.

On the other hand, we found clear association between MSRF and subjective measures of ANS dysfunction. Since the introduction of COMPASS-31, it has become possible to systematically assess quantitative autonomic symptoms. One of the initial studies investigating the relationship of autonomic symptom burden to quality of life, fatigue and other established disease parameters was performed by Cortez and colleagues (24). This study has shown that autonomic symptom burden is correlated with decreased quality of life and increased fatigue, despite the fact that out of 100 enrolled patients, only 41 completed COMPASS-31 questionnaire in full. Furthermore, this study did not address possible covariates of fatigue like depression or daytime sleepiness, nor did authors test whether obtained results are still significant after using multivariate regression analysis. Another study showed that COMPASS-31 predicts the level of cognitive fatigue independent of age, disease duration, EDSS, and mental impairment (25). We have confirmed this finding in our study, showing that the COMPASS-31 is the only independent predictor of cognitive fatigue. Furthermore, we have replicated the finding that the pupillomotor domain of the COMPASS-31 is an important contributor to the MSRF. A recent study investigating cognition and fatigue using pupillary responses to light, found a tendency toward a smaller pupillary response in pwMS with fatigue, possibly explaining observation of this association (26). One thing that can explain the association between MSRF and subjective dysautonomia and lack of association between MSRF and objective dysautonomia is discrepancy between patient reported symptoms and laboratory findings in structural disorders of the ANS. In line with this, one study has shown that even patients with severe orthostatic hypotension can be completely asymptomatic (27). Similarly, when we correlated domains of the COMPASS-31 and results of the cardiovascular reflexes and QSART, we only observed significant correlations between QSART results and gastrointestinal and secretomotor domains of the COMPASS-31, suggesting that this dissociation in subjective and objective dysautonomia may be pertinent to MS, as well.

Pathophysiology of MSRF is very complex, and the role of structural or functional brain abnormalities, the contribution of neurochemical imbalance, neuroendocrine dysfunction, neuroimmune dysregulation and peripheral nervous system contribution, have all been explored in the generation of this symptom (28).

Several of these hypotheses are interesting regarding the possible role of autonomic nervous system dysfunction in MSRF. The presence of immunological dysregulation is the basis of MS, and inflammatory and neuroendocrine factors may differentially mediate fatigue (29). Recently it has been suggested that pathologic interactions between the immune and the autonomic systems may fail to trigger anti-inflammatory mechanisms,

which are essential to prevent repeated inflammatory attacks, a key pathogenic feature of MS (30). The parasympathetic part of the ANS has a major role in alerting the central nervous system about the presence of inflammation via inflammatory cytokines (31). These afferent signals are transmitted by the vagal nerve and trigger an anti-inflammatory response, termed “cholinergic anti-inflammatory pathway” (30).

Peripheral nervous system contribution to MSRF is a controversial topic, however it has been suggested that sensory perception resulting from a complex integration of physiological, biochemical, and other sensory feedback from the periphery may contribute to MSRF (32). Interestingly, we found a significant negative correlation between MFIS result and sweat volume on different sites measured with QSART. QSART has been traditionally used as a marker of peripheral cholinergic postganglionic nerve affection, and thus its value was mainly in the diagnosis of small fiber neuropathy. As MS is a central nervous system disorder, results of our study can be interpreted in two ways: either QSART can detect central disorders of thermoregulation or peripheral nervous system is also affected in MS. An argument for the former is a study that showed that QSART values can be abnormal even with preganglionic lesions (33). An argument for the latter came from several studies questioning whether MS is a pure central nervous system disorder. Jende and colleagues have demonstrated peripheral nerve lesions in pwMS in vivo by high resolution MRI (34). These lesions are defined by an increase of proton-spin-density and a decrease of T2-relaxation time, indicating changes in the microstructural organization of the extracellular matrix in peripheral nerve tissue in MS. Furthermore, it has also been suggested that pwMS may exhibit significant small fiber damage, which is associated with neurological disability from MS (35, 36). One of the main consequences of sudomotor dysfunction in MS is heat sensitivity, and it has been suggested that heat sensitivity in MS might contribute to premature fatigue either through passively induced rises in body temperature or through exercise (37). The results of our study give a possible pathophysiological explanation of this association, although we did not assess changes in body temperature in the presented patient group. Despite this theoretical background, the relationship between fatigue symptoms and dysautonomia in MS received minor interest.

The limitations of this study are possible selection bias as not all participants of the BACIS project participated in the substudy. It has to be emphasized that we enrolled a specific group of pwMS very early in the disease course and that the percentage of patients with fatigue was comparatively low. Furthermore, not all participants had QSART performed due to financial limitations. Finally, ESS measures daytime sleepiness, a similar feeling as fatigue, however a recent study has shown that ESS was significantly associated with sleepiness, tiredness, and lack of energy, but not fatigue (38).

Despite of this, the results of this study suggest an association between autonomic dysfunction, especially sudomotor dysfunction and fatigue in MS patients. Further studies with long term follow-up are warranted.

## References

1. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. *J Psychosom Res* 2004;56:157-70.
2. Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. *Nat Rev Neurol* 2017;13:662-675.
3. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. *Can J Neurol Sci* 1994;21:9-14.
4. Miller P, Soundy A. The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis. *J Neurol Sci* 2017;381:41-54.
5. Filippi M, Rocca MA, Colombo B, Falini A, Codella M, Scotti G, Comi G. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. *Neuroimage* 2002;15:559-67.
6. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? *J Neurol Neurosurg Psychiatry* 2006;77:34-9.
7. Gottschalk M, Kümpfel T, Flachenecker P, Uhr M, Trenkwalder C, Holsboer F, Weber F. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. *Arch Neurol* 2005;62:277-80.
8. Solaro C, Gamberini G, Masuccio FG. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. *CNS Drugs* 2018;32:117-133.
9. Barun B. Pathophysiological background and clinical characteristics of sleep disorders in multiple sclerosis. *Clin Neurol Neurosurg* 2013;115 Suppl 1:S82-5.
10. Sternberg Z. Impaired Neurovisceral Integration of Cardiovascular Modulation Contributes to Multiple Sclerosis Morbidities. *Mol Neurobiol* 2017;54:362-374.
11. Habek M, Crnošija L, Lovrić M, Junaković A, Krbot Skorić M, Adamec I. Sympathetic cardiovascular and sudomotor functions are frequently affected in early multiple sclerosis. *Clin Auton Res* 2016;26:385-393.
12. <http://www.hrzz.hr/default.aspx?id=1205&pid=2622&rok=2013-11>, accessed on March 16, 2018.)
13. Novak P. Quantitative autonomic testing. *J Vis Exp* 2011;(53). pii: 2502. doi: 10.3791/2502.
14. Freeman R. Assessment of cardiovascular autonomic function. *Clin Neurophysiol* 2006;117:716-730.
15. Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. *Mayo Clin Proc* 1993;68:748-752.
16. Drulović J, Gavrilović A, Crnošija L, Kisić-Tepavčević D, Krbot Skorić M, Ivanović J, Adamec I, Dujmović I, Junaković A, Marić G, Martinović V, Pekmezović T, Habek M. Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosis. *Croat Med J* 2017;58:342-348.
17. Pecotic R, Dodig IP, Valic M, Ivkovic N, Dogas Z. The evaluation of the Croatian version of the Epworth sleepiness scale and STOP questionnaire as screening tools for obstructive sleep apnea syndrome. *Sleep Breath* 2012;16:793-802.
18. Sacco R, Santangelo G, Stamenova S, Bisecco A, Bonavita S, Lavorgna L, Trojano L, D'Ambrosio A, Tedeschi G, Gallo A. Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. *Eur J Neurol* 2016;23:744-50.

19. Flachenecker P, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. *Mult Scler* 2002;8:523-6.
20. Veauthier C, Radbruch H, Gaede G, Pfueller CF, Dörr J, Bellmann-Strobl J, Wernecke KD, Zipp F, Paul F, Sieb JP. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. *Mult Scler* 2011;17:613-22.
21. Keselbrener L, Akselrod S, Ahiron A, Eldar M, Barak Y, Rotstein Z. Is fatigue in patients with multiple sclerosis related to autonomic dysfunction? *Clin Auton Res* 2000;10:169-75.
22. Merkelbach S, Dillmann U, Kölmel C, Holz I, Müller M. Cardiovascular autonomic dysregulation and fatigue in multiple sclerosis. *Mult Scler* 2001;7:320-6.
23. Flachenecker P, Rufer A, Bihler I, Hippel C, Reiners K, Toyka KV, Kesselring J. Fatigue in MS is related to sympathetic vasomotor dysfunction. *Neurology* 2003;61:851-3.
24. Cortez MM, Nagi Reddy SK, Goodman B, Carter JL, Wingerchuk DM. Autonomic symptom burden is associated with MS-related fatigue and quality of life. *Mult Scler Relat Disord* 2015;4:258-63.
25. Sander C, Hildebrandt H, Schlake HP, Eling P, Hanken K. Subjective cognitive fatigue and autonomic abnormalities in multiple sclerosis patients. *Front Neurol* 2017;8:475.
26. de Rodez Benavent SA, Nygaard GO, Harbo HF, Tønnesen S, Sowa P, Landrø NI, Wendel-Haga M, Etholm L, Nilsen KB, Drolsum L, Kerty E, Celius EG, Laeng B. Fatigue and cognition: Pupillary responses to problem-solving in early multiple sclerosis patients. *Brain Behav* 2017;7:e00717.
27. Arbogast SD, Alsheklee A, Hussain Z, McNeeley K, Chelimsky TC. Hypotension unawareness in profound orthostatic hypotension. *Am J Med* 2009;122:574-80.
28. Ayache SS, Chalah MA. Fatigue in multiple sclerosis - Insights into evaluation and management. *Neurophysiol Clin* 2017;47:139-171.
29. Gold SM, Krüger S, Ziegler KJ, Krieger T, Schulz KH, Otte C, Heesen C. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. *J Neurol Neurosurg Psychiatry* 2011;82:814-8.
30. Racosta JM, Kimpinski K. Autonomic dysfunction, immune regulation, and multiple sclerosis. *Clin Auton Res* 2016;26:23-31.
31. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol* 2007;81:1-5.
32. Noakes TD, Clair Gibson A, Lambert EV. From catastrophe to complexity: a novel model of integrative central neural regulation of effort and fatigue during exercise in humans: summary and conclusions. *Br J Sports Med* 2005;39:120-4.
33. Davis SL, Wilson TE, Vener JM, Crandall CG, Petajan JH, White AT. Pilocarpine-induced sweat gland function in individuals with multiple sclerosis. *J Appl Physiol* (1985) 2005;98:1740-4.
34. Jende JME, Hauck GH, Diem R, Weiler M, Heiland S, Wildemann B et al. Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography. *Ann Neurol* 2017;82:676-685.
35. Khan A, Kamran S, Ponirakis G, Akhtar N, Khan R, George P, Babu BM, Ibrahim FM, Petropoulos IN, Canibano BG, Wilins SS, Deleu D, Shuaib A, Malik RA. Peripheral neuropathy in patients with multiple sclerosis. *PLoS One* 2018;13:e0193270.

36. Adamec I, Crnošija L, Junaković A, Krbot Skorić M, Habek M. Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype. *Clin Neurophysiol* 2018;129:1588-1594.
37. Marino F. Heat reactions in multiple sclerosis: An overlooked paradigm in the study of comparative fatigue. *Int J Hyperthermia* 2009;25:34–40.
38. Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. *Chest* 2000 Aug;118:372-9.

## Tables

**Table 1.** Baseline patients' characteristics.

	Mean/median	Standard deviation	Range
Age (years)	33.8	9.1	
Sex (females)	51		
EDSS	1.0		0-4.0
Scales			
MFIS	22		0-70
ESS	5		0-18
BDI-2	4		0-50
COMPASS-31	8.5		0-57.7
OI	0		0-32
Vasomotor	0		0-4.2
Secretomotor	0		0-6.4
GI	2.7		0-13.4
Bladder	0		0-7.8
Pupillomotor	1		0-4.0
ANS tests			
VR	2.2	0.5	
RSA	21.9	8.2	
QSART forearm ( $\mu$ l)*	0.885	0.727	
QSART proximal lower leg ( $\mu$ l)*	1.099	0.805	
QSART distal lower leg ( $\mu$ l)*	1.425	0.942	
QSART foot ( $\mu$ l)*	0.597	0.420	
CASS total*	1		0-5
CASS adrenergic	0		0-3
CASS cardiovagal	0		0-1
CASS sudomotor*	0		0-3

\*QSART results were available for 62 patients.

EDSS – expanded disability status scale, COMPASS-31 - Composite Autonomic System Score-31, OI – orthostatic intolerance; GI – gastrointestinal; MFIS - Modified Fatigue Impact Scale, BDI-2 - Beck depression scale, ESS - Epworth Sleepiness Scale (ESS), VR – Valslva ratio, RSA – respiratory sinus arrhythmia, QSART - Quantitative Sudomotor Axon Reflex Test; CASS - Composite autonomic scoring scale

**Table 2.** Differences in all studied parameters between fatigued and non-fatigued MS patients defined either as MFIS  $\geq 45$  or  $\geq 38$ .

	MFIS<45	MFIS $\geq 45$	p	MFIS<38	MFIS $\geq 38$	p
Age (years) <sup>#</sup>	32.3 $\pm$ 7.8	44.4 $\pm$ 11.2	<b>&lt;0.001</b>	31.6 $\pm$ 7.5	40.8 $\pm$ 10.6	<b>&lt;0.001</b>
Sex (females)	43	8	0.43	36	15	0.13
EDSS <sup>#</sup>	1	2	0.06	1	1.5	0.10
Scales						
ESS <sup>#</sup>	5	6	0.51	5	11	<b>0.009</b>
BDI-2 <sup>#</sup>	2.5	20.5	<b>&lt;0.001</b>	2	16	<b>&lt;0.001</b>
COMPASS-31*	6.5913	38.2579	<b>0.001</b>	6.1786	24.8016	<b>&lt;0.001</b>
OI*	0	16	0.01	0	16	0.007
Vasomotor*	0	0	0.009	0	0	0.008
Secretomotor*	0	4.2857	<b>0.001</b>	0	4.2857	<b>0.002</b>
GI*	2.6786	6.2500	<b>&lt;0.001</b>	1.7857	5.3571	<b>0.001</b>
Bladder*	0	2.2222	<b>0.001</b>	0	1.1111	<b>0.002</b>
Pupillomotor*	1	2.3333	<b>&lt;0.001</b>	1	2.0000	<b>&lt;0.001</b>
ANS tests						
VR <sup>#</sup>	2.3 $\pm$ 0.5	1.8 $\pm$ 0.3	0.03	2.3 $\pm$ 0.5	2.0 $\pm$ 0.3	0.04
RSA <sup>#</sup>	22.5 $\pm$ 8.3	17.9 $\pm$ 6.5	0.14	23.0 $\pm$ 8.6	18.3 $\pm$ 5.4	0.02
QSART forearm ( $\mu$ ) <sup>**</sup>	0.94 $\pm$ 0.75	0.52 $\pm$ 0.44	0.131	1.02 $\pm$ 0.77	0.50 $\pm$ 0.38	0.013
QSART proximal lower leg ( $\mu$ ) <sup>**</sup>	1.15 $\pm$ 0.83	0.78 $\pm$ 0.53	0.202	1.23 $\pm$ 0.87	0.74 $\pm$ 0.44	0.030
QSART distal leg ( $\mu$ ) <sup>**</sup>	1.25	0.64	<b>0.009</b>	1.56 $\pm$ 0.96	1.06 $\pm$ 0.82	0.060
QSART foot ( $\mu$ ) <sup>**</sup>	0.64 $\pm$ 0.43	0.37 $\pm$ 0.23	0.075	0.68 $\pm$ 0.44	0.37 $\pm$ 0.25	<b>0.001</b>
CASS total <sup>**</sup>	1	2	0.07	1	2	0.045
CASS adrenergic <sup>**</sup>	0	0.5	0.53	0	1	0.10
CASS cardiovagal <sup>**</sup>	0	0	0.46	0	0	0.26
CASS sudomotor <sup>**</sup>	0	1	0.07	0	1	0.20

\* Bonferroni corrected p-value = 0.007; <sup>#</sup> Bonferroni corrected p-value = 0.017; <sup>\*\*</sup>

Bonferroni corrected p-value = 0.013; Bold indicates statistically significant difference.

EDSS – expanded disability status scale, COMPASS-31 - Composite Autonomic System Score-31, OI – orthostatic intolerance; GI – gastrointestinal; MFIS - Modified Fatigue Impact Scale, BDI-2 - Beck depression scale, ESS - Epworth Sleepiness Scale (ESS), VR – Valsalva ratio, RSA – respiratory sinus arrhythmia, QSART - Quantitative Sudomotor Axon Reflex Test; CASS - Composite autonomic scoring scale

**Table 3.** Regression analysis with different types of fatigue (physical, cognitive and psychosocial) as outcome variables.

Predictor	B	P value
Model with cognitive fatigue, (F=6.874, p<0.001), with a R <sup>2</sup> =0.411		
Sex	-1.011	0.620
Age	0.069	0.530
Use of DMT	-0.995	0.585
ESS	0.353	0.113
BDI-2	6.034	0.114
COMPASS-31*	0.216	<b>0.012</b>
Model with physical fatigue, (F=13.516, p<0.001), with a R <sup>2</sup> =0.579		
Sex	0.137	0.936
Age	0.044	0.630
Use of DMT	-1.275	0.402
ESS*	0.645	<b>0.001</b>
BDI-2*	7.500	<b>0.020</b>
COMPASS-31*	0.219	<b>0.003</b>
Model with psychosocial fatigue, (F=13.938, p<0.001), with a R <sup>2</sup> =0.586		
Sex	0.216	0.608
Age	0.010	0.675
Use of DMT	-0.320	0.396
ESS*	0.142	<b>0.003</b>
BDI-2*	2.647	<b>0.001</b>
COMPASS-31*	0.045	<b>0.011</b>

COMPASS-31 - Composite Autonomic System Score-31, BDI-2 - Beck depression scale, ESS - Epworth Sleepiness Scale (ESS), DMT – disease modifying therapy; \*statistically significant predictor



## Figures

**Figure 1.** Correlations between Modified Fatigue Impact Scale (MFIS) and Quantitative Sudomotor Axon Reflex Test (QSART) of the forearm, proximal lower leg, distal lower leg and foot ( $r_s = -0.379$ ,  $p=0.003$ ,  $r_s = -0.356$ ,  $p=0.005$ ,  $r_s = -0.345$ ,  $p=0.006$  and  $r_s = -0.249$ ,  $p=0.051$ , respectively; Bonferroni corrected p-value = 0.0125)

**Figure 2.** Correlation between Modified Fatigue Impact Scale (MFIS) and Composite Autonomic System Score-31 (COMPASS-31) ( $r_s=0.607$ ,  $p<0.001$ ; Bonferroni corrected p-value = 0.007)



